Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Drug pipeline: Q212

Subjects

An Erratum to this article was published on 07 December 2012

This article has been updated

In the first two quarters of 2012, there have been 12 approvals (NME and biologics) compared with 30 for 2011. The appovals of two obesity drugs, Qsymia and Belviq, a plant produced replacement enzyme for Gaucher's disease, Elelyso, and a PET imaging agent for Alzheimer's, Amyvid, were of note. Sodium glucose transporter 2 inhibitors continue to impress in the clinic. But trials of Pfizer's flagship Alzheimer's therapy bapineuzumab were finally suspended.

Notable regulatory approvals (Q2 2012)

Notable regulatory setbacks (Q2 2012)

Notable upcoming regulatory decisions (Q4 2012)

FDA approvals by lead indication area

Notable trial results (Q2 2012)

Change history

  • 07 December 2012

    In the version of the article originally published, the Thrombogenics drug Jetrea (recombinant microplasmin) was listed in “Notable upcoming regulatory decisions” as indicated for thyroid cancer. It should have read vitreomacular adhesion. The error has been corrected in the HMTL and PDF versions of the article.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

DeFrancesco, L. Drug pipeline: Q212. Nat Biotechnol 30, 817 (2012). https://doi.org/10.1038/nbt.2359

Download citation

Further reading

Search

Quick links